FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945870562> ?p ?o ?g. }

• W2945870562 endingPage "179" @default.
• W2945870562 startingPage "164" @default.
• W2945870562 abstract "The CYD-TDV vaccine is licensed in multiple endemic countries based on vaccine efficacy (VE) against symptomatic, virologically confirmed dengue demonstrated in two phase 3 trials (CYD14, 2- to 14-year-olds, Asia; CYD15, 9- to 16-year-olds, Latin America). 50% plaque reduction neutralization test (PRNT50) titers at baseline and month 13 (post-vaccination) were associated with VE and may enable bridging VE to adults. Two phase 2 trials of CYD-TDV measured baseline and month 13 PRNT50 titers: CYD22 (9- to 45-year-olds, Vietnam) and CYD47 (18- to 45-year-olds, India). 50% plaque reduction neutralization test distributions were compared between age cohorts, and four versions of an epidemiological bridging method were used to estimate VE against any serotype (dengue virus [DENV]-Any) and against each serotype over 25 months post first vaccination in a hypothetical CYD14 + CYD15 18- to 45-year-old cohort (bridging population 1) and in the actual CYD47 18- to 45-year-old cohort (bridging population 2). Baseline and month 13 geometric mean PRNT50 titers to each serotype were significantly greater in 18- to 45-year-olds than 9- to 16-year-olds for all comparisons. The four methods estimated VE against DENV-Any at 75.3–86.0% (95% CIs spanning 52.5–100%) for bridging population 1 and 68.4–77.5% (95% CIs spanning 42.3–88.5%) for bridging population 2. The vaccine efficacy against serotype 1, 2, 3, and 4 was estimated at 56.9–76.9%, 68.3–85.8%, 91.4–95.0%, and 93.2–100% (bridging population 1) and 44.5–66.9%, 53.2–69.2%, 79.8–92.0%, and 90.6–95.0% (bridging population 2), respectively; thus, CYD-TDV would likely confer improved efficacy in adults than 9- to 16-year-olds. Using the same methods, we predicted VE against hospitalized DENV-Any over 72 months of follow-up, with estimates 59.1–73.5% (95% CIs spanning 40.9–92.2%) for bridging population 1 and 50.9–65.9% (95% CIs spanning 38.1–82.1%) for bridging population 2." @default.
• W2945870562 created "2019-05-29" @default.
• W2945870562 creator A5005437196 @default.
• W2945870562 creator A5010611091 @default.
• W2945870562 creator A5013797154 @default.
• W2945870562 creator A5017338936 @default.
• W2945870562 creator A5023018481 @default.
• W2945870562 creator A5024014414 @default.
• W2945870562 creator A5038262133 @default.
• W2945870562 creator A5040760200 @default.
• W2945870562 creator A5046294205 @default.
• W2945870562 creator A5047380875 @default.
• W2945870562 creator A5049491205 @default.
• W2945870562 creator A5067347116 @default.
• W2945870562 creator A5069748200 @default.
• W2945870562 creator A5081709395 @default.
• W2945870562 creator A5085731242 @default.
• W2945870562 creator A5085762412 @default.
• W2945870562 date "2019-07-03" @default.
• W2945870562 modified "2023-10-01" @default.
• W2945870562 title "Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response" @default.
• W2945870562 cites W1017348960 @default.
• W2945870562 cites W1120017812 @default.
• W2945870562 cites W1674686726 @default.
• W2945870562 cites W1991673588 @default.
• W2945870562 cites W2021113575 @default.
• W2945870562 cites W2026562276 @default.
• W2945870562 cites W2047933983 @default.
• W2945870562 cites W2066648075 @default.
• W2945870562 cites W2082278155 @default.
• W2945870562 cites W2097270831 @default.
• W2945870562 cites W2097288560 @default.
• W2945870562 cites W2102296058 @default.
• W2945870562 cites W2103250575 @default.
• W2945870562 cites W2107939173 @default.
• W2945870562 cites W2116471574 @default.
• W2945870562 cites W2123053752 @default.
• W2945870562 cites W2126789944 @default.
• W2945870562 cites W2131222241 @default.
• W2945870562 cites W2131427505 @default.
• W2945870562 cites W2135141456 @default.
• W2945870562 cites W2137488647 @default.
• W2945870562 cites W2141264905 @default.
• W2945870562 cites W2147049904 @default.
• W2945870562 cites W2158773979 @default.
• W2945870562 cites W2160285795 @default.
• W2945870562 cites W2160358721 @default.
• W2945870562 cites W2161824746 @default.
• W2945870562 cites W2164079841 @default.
• W2945870562 cites W2170534481 @default.
• W2945870562 cites W2171207651 @default.
• W2945870562 cites W2187093363 @default.
• W2945870562 cites W2195096572 @default.
• W2945870562 cites W2222158372 @default.
• W2945870562 cites W2233660390 @default.
• W2945870562 cites W2327664245 @default.
• W2945870562 cites W2333736406 @default.
• W2945870562 cites W2511118048 @default.
• W2945870562 cites W2512428562 @default.
• W2945870562 cites W2531376405 @default.
• W2945870562 cites W2550539193 @default.
• W2945870562 cites W2765619750 @default.
• W2945870562 cites W2769142594 @default.
• W2945870562 cites W2803273577 @default.
• W2945870562 cites W2804456027 @default.
• W2945870562 cites W2807989886 @default.
• W2945870562 cites W2888408905 @default.
• W2945870562 cites W2913714413 @default.
• W2945870562 doi "https://doi.org/10.4269/ajtmh.18-0534" @default.
• W2945870562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6609170" @default.
• W2945870562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31115304" @default.
• W2945870562 hasPublicationYear "2019" @default.
• W2945870562 type Work @default.
• W2945870562 sameAs 2945870562 @default.
• W2945870562 citedByCount "9" @default.
• W2945870562 countsByYear W29458705622020 @default.
• W2945870562 countsByYear W29458705622021 @default.
• W2945870562 countsByYear W29458705622022 @default.
• W2945870562 countsByYear W29458705622023 @default.
• W2945870562 crossrefType "journal-article" @default.
• W2945870562 hasAuthorship W2945870562A5005437196 @default.
• W2945870562 hasAuthorship W2945870562A5010611091 @default.
• W2945870562 hasAuthorship W2945870562A5013797154 @default.
• W2945870562 hasAuthorship W2945870562A5017338936 @default.
• W2945870562 hasAuthorship W2945870562A5023018481 @default.
• W2945870562 hasAuthorship W2945870562A5024014414 @default.
• W2945870562 hasAuthorship W2945870562A5038262133 @default.
• W2945870562 hasAuthorship W2945870562A5040760200 @default.
• W2945870562 hasAuthorship W2945870562A5046294205 @default.
• W2945870562 hasAuthorship W2945870562A5047380875 @default.
• W2945870562 hasAuthorship W2945870562A5049491205 @default.
• W2945870562 hasAuthorship W2945870562A5067347116 @default.
• W2945870562 hasAuthorship W2945870562A5069748200 @default.
• W2945870562 hasAuthorship W2945870562A5081709395 @default.
• W2945870562 hasAuthorship W2945870562A5085731242 @default.
• W2945870562 hasAuthorship W2945870562A5085762412 @default.
• W2945870562 hasBestOaLocation W29458705621 @default.
• W2945870562 hasConcept C10389963 @default.

• next